Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

X5 Group revenue for 9 months of 2023 increased by 19.3%

10/17/23 FIVE

Lenta acquired a chain of convenience stores Monetka

10/17/23 LENT

Positive Technologies will hold its first additional share issue to motivate employees

10/17/23 POSI

Yuzhuralzoloto is going to IPO again

10/17/23 UGLD

Board of Directors of Mordovenergosbyt recommended that dividends

10/17/23 MRSB

Bank of Russia registered the prospectus of X5 Retail Group receipts

10/17/23 FIVE

Ozon opened a logistics center in Teuchezhsky district of Adygeya

10/17/23 OZON

Positive Technologies updated its dividend policy

10/17/23 POSI

Ministry of Finance to withdraw banks' excess profits through dividends

10/17/23 SBER

Mosenergo increased electricity generation by 1.5%

10/16/23 MSNG